FTSE MIB
29.928,45 +191,07 (+0,64%) Dow Jones
36.185,63 +234,74 (+0,65%) Nasdaq
14.278,00 +51,78 (+0,36%) Nikkei 225
33.431,51 -55,38 (-0,17%) Petrolio
74,39 -1,57 (-2,07%) Bitcoin EUR
35.661,14 +937,21 (+2,70%)
Anavex Life Sciences Corp. (0HFR.L)
| Chiusura precedente | 7,15 |
| Aperto | 7,16 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 7,14 - 7,59 |
| Intervallo di 52 settimane | 4,93 - 13,78 |
| Volume | |
| Media Volume | 4.200 |
| Capitalizzazione | 4,29M |
| Beta (5 anni mensile) | 0,72 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,58 |
| Prossima data utili | 05 feb 2024 - 09 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Significant Reduction of Amyloid Beta Biomarkers of Alzheimer’s PathologyNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced today that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug blarcamesine (ANA
- GlobeNewswire
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board. Pr
- GlobeNewswire
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023 Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study in Alzheimer’s disease with convenient oral treatment to be released in the second half of 2023 Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Compa
